A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 29,300 shares of INMB stock, worth $131,557. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,300
Previous 12,400 136.29%
Holding current value
$131,557
Previous $109,000 44.04%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.86 - $9.86 $74,970 - $152,100
15,426 Added 50.26%
46,116 $248,000
Q2 2024

Aug 14, 2024

BUY
$7.15 - $11.84 $219,219 - $363,014
30,660 Added 102200.0%
30,690 $270,000
Q1 2024

May 15, 2024

SELL
$10.53 - $14.01 $356,135 - $473,832
-33,821 Reduced 99.91%
30 $0
Q4 2023

Feb 14, 2024

BUY
$6.6 - $11.52 $129,333 - $225,745
19,596 Added 137.47%
33,851 $381,000
Q3 2023

Nov 14, 2023

SELL
$6.61 - $10.9 $169,116 - $278,876
-25,585 Reduced 64.22%
14,255 $96,000
Q2 2023

Aug 14, 2023

BUY
$6.5 - $10.09 $7,345 - $11,401
1,130 Added 2.92%
39,840 $361,000
Q1 2023

May 15, 2023

SELL
$6.01 - $10.18 $19,929 - $33,756
-3,316 Reduced 7.89%
38,710 $250,000
Q4 2022

Feb 14, 2023

BUY
$6.13 - $7.96 $97,430 - $126,516
15,894 Added 60.82%
42,026 $266,000
Q3 2022

Nov 14, 2022

BUY
$6.04 - $10.44 $57,192 - $98,856
9,469 Added 56.83%
26,132 $162,000
Q2 2022

Aug 15, 2022

SELL
$5.48 - $8.97 $53,720 - $87,932
-9,803 Reduced 37.04%
16,663 $147,000
Q1 2022

May 16, 2022

SELL
$6.42 - $11.39 $265,961 - $471,853
-41,427 Reduced 61.02%
26,466 $223,000
Q4 2021

Feb 14, 2022

BUY
$9.97 - $20.38 $151,553 - $309,796
15,201 Added 28.85%
67,893 $692,000
Q3 2021

Nov 15, 2021

SELL
$14.13 - $27.85 $47,533 - $93,687
-3,364 Reduced 6.0%
52,692 $1.02 Million
Q2 2021

Aug 16, 2021

BUY
$9.29 - $19.33 $520,760 - $1.08 Million
56,056 New
56,056 $984,000
Q2 2019

Aug 14, 2019

SELL
$7.45 - $11.0 $75,922 - $112,101
-10,191 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$7.08 - $8.2 $72,152 - $83,566
10,191 New
10,191 $0

Others Institutions Holding INMB

About Inmune Bio, Inc.


  • Ticker INMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,946,000
  • Market Cap $80.6M
  • Description
  • INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...
More about INMB
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.